Cannabis and SSRIs
What's known, suspected, and unknown about combining cannabis with selective serotonin reuptake inhibitors.
Most people taking an SSRI who also use cannabis do fine, but 'fine' is not the same as 'studied.' There are almost no controlled trials of this specific combination. The real risks are pharmacokinetic interference at high CBD doses, occasional serotonin-syndrome-like case reports, and the unhelpful fact that heavy cannabis use can worsen the very anxiety and depression an SSRI is trying to treat. Anyone telling you they know exactly how weed interacts with your Lexapro is overselling.
Not Medical Advice
This article is not medical advice. It summarizes published evidence as of writing. Do not start, stop, or change an SSRI dose based on what you read here. SSRI discontinuation can cause significant withdrawal effects, and untreated depression can be dangerous. Talk to a prescriber who knows your full history before combining cannabis with any psychiatric medication.
Plain-Language Summary
SSRIs (sertraline, fluoxetine, escitalopram, etc.) raise serotonin signaling in the brain to treat depression, anxiety, OCD, and PTSD. Cannabis acts mainly on the endocannabinoid system (CB1, CB2) but also touches serotonin pathways indirectly. There is no large, high-quality clinical trial of cannabis combined with SSRIs in humans. What we have is: pharmacology that predicts modest interactions, a small number of case reports, observational data, and a lot of patient self-report. The combination is common and rarely catastrophic, but 'common' is not the same as 'safe and effective.' Weak / limited
What Probably Works (Relatively Stronger Evidence)
Honestly, very little in this specific combination meets a 'probably works' bar. The strongest claim that survives scrutiny is narrow:
- High-dose CBD inhibits CYP450 enzymes (CYP2C19, CYP3A4, CYP2D6), which metabolize many SSRIs. This is a pharmacokinetic fact, not a clinical recommendation. It means a person on, say, citalopram or escitalopram who takes 300+ mg/day of CBD may have higher SSRI blood levels than expected. Strong evidence [1][2]
- Heavy, daily cannabis use is associated with worse outcomes in people being treated for depression and anxiety, including in SSRI-treated populations. Direction of causation is unclear, but the association is consistent. Strong evidence [3][4]
That is roughly the floor of what I'd call solid.
What Might Work (Weak or Preliminary Evidence)
- CBD as an adjunct for anxiety in people already on SSRIs. Small open-label and short RCT data suggest CBD has anxiolytic effects in social anxiety and generalized anxiety, but trials specifically in SSRI-treated patients are essentially absent. Weak / limited [5][6]
- Low-dose THC for sleep onset in depressed patients on SSRIs. Patients report this constantly. Controlled data in this exact population: none. Anecdote
- Cannabis reducing SSRI-related sexual side effects. Widely claimed online. No controlled trials. Plausible mechanism (dopaminergic disinhibition, anxiolysis) but plausible is not proven. Anecdote
- CBD for SSRI-associated emotional blunting. Sometimes claimed; no human trial evidence. No data
What Doesn't Work or Has Weak Evidence
- 'Cannabis can replace your SSRI.' No. There is no evidence that cannabis is a substitute for an SSRI for major depressive disorder, OCD, panic disorder, or PTSD as first-line treatment. Observational substitution studies are confounded and low quality. [evidence:weak / disputed] [7]
- Indica strains for depression, sativa for energy. This is folklore. The indica/sativa labels do not reliably predict chemistry or effect. Disputed [8]
- High-THC products as antidepressants. Heavier THC exposure is associated with increased depressive and anxious symptoms over time in several cohorts, not fewer. Strong evidence [3][4]
- CBD 'boosting' SSRI effectiveness. No clinical trial supports this. No data
What We Don't Know
The honest list is long:
- Whether low-dose THC plus an SSRI is safer or riskier than either alone for anxiety.
- Whether CBD meaningfully alters clinical SSRI response at recreational/wellness doses (5–50 mg).
- Whether cannabis use changes SSRI discontinuation syndrome.
- Dose–response curves for any of the above.
- Long-term effects of chronic co-use on neuroplasticity, the stated mechanism by which SSRIs are thought to work.
No registered large RCT has answered these. Patients are running this experiment on themselves in real time. No data
Comparison With Standard Treatments
For the conditions SSRIs treat, the evidence base for first-line options is:
- SSRIs: large RCT base; modest but real effect sizes in moderate-to-severe depression and several anxiety disorders. Strong evidence [9]
- CBT and related psychotherapies: comparable effect sizes to SSRIs for many anxiety disorders; durable. Strong evidence [9]
- Exercise: meaningful antidepressant effect, especially in mild-to-moderate depression. Strong evidence [10]
- Cannabis (any form) as monotherapy for depression/anxiety: no comparable evidence base. Best characterized as 'unstudied at the level required to recommend.' Weak / limited
The relevant comparison is not 'cannabis vs SSRI.' It is 'cannabis added to an evidence-based regimen — does it help, hurt, or do nothing?' We don't know.
Risks and Practical Considerations
- Serotonin syndrome: Theoretically possible, especially with MDMA, tramadol, or other serotonergics added in. Case reports involving cannabis plus SSRIs exist but are rare; cannabis alone is a weak serotonergic at best. Weak / limited [11]
- Pharmacokinetic interaction: Most relevant with high-dose pharmaceutical CBD (e.g., Epidiolex-range doses). Recreational CBD doses are less likely to matter but not zero. Strong evidence [1][2]
- Worsening of underlying illness: Heavy THC use is linked to increased depression, anxiety, and psychosis risk, particularly in adolescents and young adults. Strong evidence [3][4][12]
- Cannabis use disorder: Roughly 1 in 5 regular adult users develop problematic use; this is higher in people with mood/anxiety disorders. Strong evidence [12]
- Impaired SSRI adherence: Intoxication and disorganized routines correlate with missed doses, which matters for SSRIs. Weak / limited
- Driving and cognition: Both classes can impair cognition; combined effects on driving are under-studied. Weak / limited
If you and your prescriber decide co-use is acceptable, the conservative pattern most clinicians describe in practice is: stable SSRI dose first, then low and infrequent cannabis, prefer balanced or CBD-leaning products over high-THC concentrates, and re-evaluate symptoms honestly at 4–8 weeks. That is clinical convention, not a trial result. Anecdote
Sources
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Balachandran P, Elsohly M, Hill KP. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. Journal of General Internal Medicine. 2021;36(7):2074-2084.
- Peer-reviewed Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(4):426-434.
- Peer-reviewed Lev-Ran S, Roerecke M, Le Foll B, et al. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychological Medicine. 2014;44(4):797-810.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-26.
- Peer-reviewed Skelley JW, Deas CM, Curren Z, Ennis J. Use of cannabidiol in anxiety and anxiety-related disorders. Journal of the American Pharmacists Association. 2020;60(1):253-261.
- Peer-reviewed Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry. 2019;6(12):995-1010.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.
- Peer-reviewed Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357-1366.
- Peer-reviewed Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. British Journal of Sports Medicine. 2023;57(18):1203-1209.
- Peer-reviewed Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. The Ochsner Journal. 2013;13(4):533-540.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Depression — What the evidence actually says about using cannabis for depressive disorders, separating...
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...